“I want the Diabetes Community to know that I know, and I’m listening and I do hear you and that’s why we’ve made customer experiences in terms of innovations and support our top priorities at Medtronic Diabetes.” -Sean Salmon, EVP and President of Medtronic Diabetes
8/18/2020 - Part 1
On August, 11 2020 Medtronic Diabetes announced its plans to acquire Companion Medical, makers of the InPen, the only FDA cleared smart insulin pen. Medtronic tasked us to collect questions from the Diabetes Community for Sean Salmon, so that’s what we did. Since the acquisition has not officially closed, this episode is part 1 of a 2 part series and if you don’t hear your question on this interview, check back for part 2 after the acquisition closes.
Disclaimer: Rob Howe is a paid consultant of Medtronic Diabetes, this podcast was made possible by Medtronic but Rob’s thoughts and opinions are his own.
In this episode, Rob and Sean discuss:
-What makes Sean so excited about the planned acquisition of Companion Medical
-Why adding a Smart Insulin Pen to Medtronic is so important
-Areas where Sean is actively working to help Medtronic improve (CGM)
-Addressing questions from community members about Medtronic Customer Service
-What Medtronic’s acquisition of Companion means for current InPen users
-Addressing questions about Dexcom integration now that Medtronic is acquiring InPen
-Discussing the concept of Pump Breaks and why it’s important to Medtronic to offer a solution for patients
Listen to Sean’s first interview with Diabetics Doing Things